EEF2K inhibition synergizes with Glutaminase and eIF4EBP1 inhibitors to suppress triple-negative breast cancer cell growth; impact on the proteome
Ontology highlight
ABSTRACT: The eukaryotic elongation factor-2 kinase, eEF2K, restricts protein translation elongation, and was identified as a potential therapeutic target for diverse types of cancers including triple negative breast cancer (TNBC; PMID: 25330770). We have recently found that inhibition of eEF2K synergizes with depletion of eukaryotic translation initiation factor 4E-binding protein 1 (eIF4EBP1; 4E-BP1), a suppressor of eukaryotic protein translation initiation factor 4E (eIF4E), leading to effective growth suppression of TNBC cells in culture. We performed LC-MS/MS analysis following depletion of eEF2K and/or 4EBP in a TNBC cell line, Hs578t (YoungJun Ju & Eldad Zacksenhaus, manuscript in revisions). Depletion of these factors had overlapping effects on the proteome with the highest impact on Collagen containing extracellular matrix (e.g. COL1A1). The complete LC-MS/MS data sets (control vehicle; eEF2K-depletion, 4EBP1-depletion; combined eEF2k plus 4EBP1-depletion) are provided herein.
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Homo Sapiens (ncbitaxon:9606)
SUBMITTER: Eldad Zacksenhaus YoungJun Ju
PROVIDER: MSV000086059 | MassIVE |
SECONDARY ACCESSION(S): PXD021276
REPOSITORIES: MassIVE
ACCESS DATA